Otros artículos de José Antonio Palma Aguirre
Castañeda Hernández G, Hoyo Vadillo C, Palma Aguirre JA, Flores Murrieta FJ. Pharmacokinetics of oral nifedipine in different populations. J Clin Pharmacol 1993; 33:140-145.
Palma Aguirre JA, Roa Mendieta A, Hernández ML, Girard-Cuesy ME, Alfaro E, et al. Pharmacokinetic and pharmacodynamic comparisons between oral and sublingual nifedipine in Mexican hypertensive patients. Proc Western Pharmacol Soc 1993; 36:137-141.
Palma Aguirre JA, Nava Rangel J, Hoyo Vadillo C, et al. Influence of Mexican diet on nifedipine pharmacodynamics in healthy volunteers. Proc West Pharmacol Soc 1994; 37:85-86.
Palma Aguirre JA, Montoya Cabrera MA, Du Souich P, Flores Murrieta FJ, Castañeda Hernández G. Discrepancy between bioavailability and hypotensive effect of oral and sublingual nifedipine. Am J Ther 1995; 2:3-9.
Palma Aguirre JA, Pérez Urizar J, Nava Rangel J, Flores Murrieta FJ, Hoyo Vadillo C, Castañeda Hernández G. Evidence against the involvement of nutritional habits in the inter-ethnic variability with regard to oral nifedipine bioavailability. Pharm Sci 1995; 1:495-497.
Castañeda Hernández G, Palma Aguirre JA, Montoya Cabrera MA, Flores Murrieta FJ. Interethnic variability in nifedipine disposition: reduced systemic plasma clearance in Mexican subjects. Br J Clin Pharmacol 1996; 41:443-444.
Isordia I, Carrasco M, Chávez Negrete A, Palma Aguirre JA, Flores Murrieta FJ, Castañeda Hernández G. Pharmacokinetic and pharmacodynamic differences between nifedipine capsule and GITS formulations in hypertensive patients. Int J Clin Pharmacol Ther 1997; 35(3):133.
Palma Aguirre JA, González Llaven J, Flores Murrieta FJ, Castañeda Hernández G. Bioavailability of oral cyclosporine in healthy Mexican volunteers: Evidence for interethnic variability. J Clin Pharmacol 1997; 37:630-634.
González Llaven J, Palma Aguirre JA, García Arreola R, Brizuela V, Nava Rangel J, Morán Lira S, Vela Ojeda J, Castañeda Hernández G, Flores Murrieta FJ. Comparative bioavailability evaluation of two cyclosporine oral formulations (sandimmune and neoral) in Mexican healthy volunteers. Arch Med Res 1999; 30(4):315-319.
Palma Aguirre JA, Halabe Cherem J, Haiko-Nellem H, Herrera E, Aburto E, Ponce Monter H. Protease inhibitor-associated hyperglycemia in Mexican patients with HIV infection. Arch Med Res 2000;31(1):81-84.
Hernández Hernández DM, Vargas Rivera J, Nava Ocampo A, Palma Aguirre JA, Sumano López H. Drug therapy and adverse drug reactions to terbutaline in obstetric patients: a prospective cohort study in hospitalized women. BioMed Central Preg Child 2002; 2:1-6.
Oropeza MV, Ponce Monter H, Villanueva Tello T, Palma Aguirre JA, Campos MG. Anatomical modulation of the uterine sensitivity to prostaglandin F2a and serotonin in non-pregnant rat. Eur J Pharmacol 2002; 446(1-3):161-166.
Rivera Espinosa L, Muriel P, Ordaz Gallo M, Pérez Urizar J, Palma Aguirre JA, Castañeda Hernández G. Ketorolac pharmacokinetics in experimental cirrhosis by bile duct ligation in the rat: unexpected reduction in oral drug bioavailability. Ann Hepatol 2003; 2(4):175-181.
Salazar González RM, Maldonado Bernal C, Ramírez Cruz NE, Ríos Sarabia N, Beltrán Nava J, Castañón J, Castillo Torres N, Palma Aguirre JA, Carrera Camargo M, López Macías C, Isibasi A. Induction of cellular immune response and anti-
Salmonella enterica serovar Typhi bactericidal antibodies in healthy volunteers by immunization with strain specific Porins. Immunol Letters 2004; 93:115-122.
Para comunicarse con José Antonio Palma Aguirre mencionar a SIIC como
referencia:
palmaguirre@yahoo.com.mx
Autor invitado
30 de agosto, 2006
Descripción aprobada
19 de octubre, 2006
Reedición siicsalud
7 de junio, 2021
